CD70 and neoplasm: The combination of restricted antigen expression demonstrated in vivo efficacy, and early clinical translation supports further development of CD70 CAR constructs, particularly those incorporating NK-optimized signaling motifs to maximize cytotoxicity while minimizing off-tumor reactivity.